Sakata Hiromi, Yonekawa Motoki, Kawamura Akio
Department of Surgery, Sapporo Hokuyu Hospital, Research Institute for Artificial Organs, Transplantation and Gene Therapy, 6-6-5-1, Higashi Sapporo, Shiroishi-Ku, Sapporo, Hokkaido 003-0006, Japan.
Transfus Apher Sci. 2006 Dec;35(3):245-51. doi: 10.1016/j.transci.2006.06.003. Epub 2006 Nov 15.
Accumulating evidences of underlining pathogenesis of sepsis have contributed to the therapeutic strategy for sepsis. Not only endotoxin and cytokine, but also signal transduction through Toll-like receptors could be a strategic target for the management of sepsis. Blood purification therapy including polymyxin B-immobilized hemoperfusion cartridge and continuous hemodiafiltration has shown the beneficial effect on patients with sepsis in Japan. Although they were initially designed to remove endotoxin and cytokines respectively, they might eliminate unexpected mediators responsible for sepsis. Further elucidation of mechanism and randomized controlled studies are needed to establish the role of blood purification therapy in sepsis.
脓毒症潜在发病机制的证据不断积累,为脓毒症的治疗策略提供了依据。不仅内毒素和细胞因子,而且通过Toll样受体的信号转导都可能成为脓毒症治疗的战略靶点。在日本,包括多粘菌素B固定化血液灌流柱和连续性血液透析滤过在内的血液净化疗法已显示出对脓毒症患者的有益效果。尽管它们最初分别设计用于清除内毒素和细胞因子,但它们可能会清除导致脓毒症的意外介质。需要进一步阐明机制并进行随机对照研究,以确立血液净化疗法在脓毒症中的作用。